Literature DB >> 28405748

Translation of imaging biomarkers from clinical research to healthcare.

Ingo Kilimann1,2, Jochen René Thyrian3, Wolfgang Hoffmann4,5, Stefan J Teipel3,6.   

Abstract

The use of biomarkers for diagnostics of Alzheimer's disease (AD) has increased over the last years in specialized care and experimental settings. With the possibly upcoming availability of disease-modifying therapeutic agents, the diagnostics and treatment of patients with cognitive impairment will change. Biomarkers will be used as theranostic markers for case finding. The development and evaluation of biomarkers can be framed in a phase model from preclinical studies through trials in expert center settings to the evaluation of biomarkers in primary care, up to testing the efficacy and the impact of biomarkers on the healthcare system. Hippocampal volumetry is the most accepted and in-depth tested biomarker for AD diagnostics and prediction of the course. Therefore, hippocampus volumetry is used to illustrate the phase model of biomarker development and present the milestones already achieved and questions still to be resolved.

Entities:  

Keywords:  Alzheimer disease; Amyloid; Cerebrospinal fluid; Positron emission tomography; Tau

Mesh：

Substances：

Year:  2017        PMID： 28405748     DOI： 10.1007/s00391-017-1225-3

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN： 0948-6704            Impact factor:   1.281


  27 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 2.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

Review 3.  Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection.

Authors:  Stefan Teipel; Alexander Drzezga; Michel J Grothe; Henryk Barthel; Gaël Chételat; Norbert Schuff; Pawel Skudlarski; Enrica Cavedo; Giovanni B Frisoni; Wolfgang Hoffmann; Jochen René Thyrian; Chris Fox; Satoshi Minoshima; Osama Sabri; Andreas Fellgiebel
Journal:  Lancet Neurol       Date:  2015-08-26       Impact factor: 44.182

4.  Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment.

Authors:  Lies Clerx; Ineke A van Rossum; Leah Burns; Dirk L Knol; Philip Scheltens; Frans Verhey; Pauline Aalten; Pablo Lapuerta; Laura van de Pol; Ronald van Schijndel; Remko de Jong; Frederik Barkhof; Robin Wolz; Daniel Rueckert; Martina Bocchetta; Magdalini Tsolaki; Flavio Nobili; Lars-Olaf Wahlund; Lennart Minthon; Lutz Frölich; Harald Hampel; Hilkka Soininen; Pieter Jelle Visser
Journal:  Neurobiol Aging       Date:  2013-03-27       Impact factor: 4.673

5.  The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity.

Authors:  Giovanni B Frisoni; Clifford R Jack; Martina Bocchetta; Corinna Bauer; Kristian S Frederiksen; Yawu Liu; Gregory Preboske; Tim Swihart; Melanie Blair; Enrica Cavedo; Michel J Grothe; Mariangela Lanfredi; Oliver Martinez; Masami Nishikawa; Marileen Portegies; Travis Stoub; Chadwich Ward; Liana G Apostolova; Rossana Ganzola; Dominik Wolf; Frederik Barkhof; George Bartzokis; Charles DeCarli; John G Csernansky; Leyla deToledo-Morrell; Mirjam I Geerlings; Jeffrey Kaye; Ronald J Killiany; Stephane Lehéricy; Hiroshi Matsuda; John O'Brien; Lisa C Silbert; Philip Scheltens; Hilkka Soininen; Stefan Teipel; Gunhild Waldemar; Andreas Fellgiebel; Josephine Barnes; Michael Firbank; Lotte Gerritsen; Wouter Henneman; Nikolai Malykhin; Jens C Pruessner; Lei Wang; Craig Watson; Henrike Wolf; Mony deLeon; Johannes Pantel; Clarissa Ferrari; Paolo Bosco; Patrizio Pasqualetti; Simon Duchesne; Henri Duvernoy; Marina Boccardi
Journal:  Alzheimers Dement       Date:  2014-09-27       Impact factor: 21.566

6.  The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation.

Authors:  M J de Leon; J Golomb; A E George; A Convit; C Y Tarshish; T McRae; S De Santi; G Smith; S H Ferris; M Noz
Journal:  AJNR Am J Neuroradiol       Date:  1993 Jul-Aug       Impact factor: 3.825

7.  Hippocampus and Basal Forebrain Volumetry for Dementia and Mild Cognitive Impairment Diagnosis: Could It Be Useful in Primary Care?

Authors:  Stefan J Teipel; Felix Keller; Jochen R Thyrian; Urs Strohmaier; Attila Altiner; Wolfgang Hoffmann; Ingo Kilimann
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Visual rating and volumetric measurement of medial temporal atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort: baseline diagnosis and the prediction of MCI outcome.

Authors:  Daniel Varon; Warren Barker; David Loewenstein; Maria Greig; Adriana Bohorquez; Isael Santos; Qian Shen; Molly Harper; Tatiana Vallejo-Luces; Ranjan Duara
Journal:  Int J Geriatr Psychiatry       Date:  2014-05-12       Impact factor: 3.485

9.  Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.

Authors:  Shannon L Risacher; Andrew J Saykin; John D West; Li Shen; Hiram A Firpi; Brenna C McDonald
Journal:  Curr Alzheimer Res       Date:  2009-08       Impact factor: 3.498

10.  Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease.

Authors:  J P Kesslak; O Nalcioglu; C W Cotman
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.